Video Experimental Relacionado
Updated: Aug 12, 2026
05:25
Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
Published on: December 29, 2021
delta 9-Tetrahidrocannabinol y la legislación de investigación terapéutica para pacientes con cáncer
JAMA
|March 18, 1983
Resumen
La Junta de Sustancias Controladas encontró Wisconsin.
Área de la Ciencia:
- Oncología Oncología.
- Farmacología Farmacología.
- Política de salud pública Política de salud pública.
Sus antecedentes:
- El Instituto Nacional del Cáncer (NCI) estableció un programa de distribución de delta 9-tetrahidrocannabinol (delta 9-THC) a los pacientes con cáncer que experimentan náuseas y vómitos inducidos por la quimioterapia.
- Los medicamentos antieméticos convencionales fueron ineficaces para estos pacientes.
Objetivo del estudio:
- Evaluar la implementación y el mecanismo de distribución del programa delta 9-THC del NCI en Wisconsin.
- Para evaluar la seguridad y eficacia del delta 9-THC para pacientes de quimioterapia.
- Analizar el impacto de la legislación propuesta de "investigación terapéutica de la marihuana" en el marco existente de aprobación de medicamentos.
Principales métodos:
- Evaluación por la Junta de Sustancias Controladas.
- Revisión de la implementación del programa NCI en Wisconsin.
- Análisis de la legislación estatal propuesta con respecto a la investigación de la marihuana terapéutica.
Principales resultados:
- El mecanismo de distribución del delta 9-THC en Wisconsin fue considerado apropiado y adecuado.
- Delta 9-THC proporcionó alivio de las náuseas y los vómitos en algunos pacientes con cáncer, pero los efectos secundarios adversos fueron comunes.
- La legislación propuesta inicialmente ignoró el marco existente de aprobación de medicamentos y amenazó el programa NCI.
- Posteriormente, la legislación se adaptó para alinearse con las estructuras legales y administrativas existentes.
Conclusiones:
- Si bien el delta 9-THC muestra cierta eficacia, persisten preguntas significativas con respecto a su seguridad y eficacia.
- Es necesaria una mayor investigación científica dentro del marco establecido de drogas de investigación.
- Los esfuerzos legislativos deben integrarse con, en lugar de interrumpir, los procesos regulatorios existentes para las sustancias controladas y la evaluación de nuevas drogas.
Videos de Conceptos Relacionados
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.